Wendy Dwyer

Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA.

Portal Instruments, Inc. operates as a medical device company that focuses on drug delivery systems. It manufactures jet injectors that deliver drugs through the skin without a needle at specific depths and volumes. The firm engages in developing and commercializing a needle-free platform technology to transform the delivery of medicines and improve the patient experience. The company was founded by Patrick A. Anquetil and Ian W. Hunter in 2012 and is headquartered in Cambridge, MA.

Part of Ipsen SA, Ipsen Bioscience, Inc. is a private company that develops and wholesales drugs. The company is based in Cambridge, MA.

Part of AstraZeneca PLC, AstraZeneca LP is a pharmaceutical company that focuses on developing and commercializing prescription drugs for various therapeutic areas. The private company is based in Wilmington, DE.

Endo Pharmaceuticals, Inc. manufactures and distributes pharmaceutical products. The company provides research and development of generic pharmaceutical products for controlling pain. Its product includes Lidoderm, Percocet, Percodan, Frova, DepoDur, and Zydone. The company is headquartered in Malvern, PA.